Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Organisation › Details

European Biotech Acquisition Corporation (Nasdaq: EBACU)

EBAC was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, re-organization, or similar business combination with one or more businesses. The Company intends to focus on identifying promising opportunities in the life sciences industry in Europe. *

	Start	2021-03-16 established (approx)
	End	2023-03-03 merged
	Group	Oculis (Group)
	Today	Oculis Holding AG (Nasdaq: OCS)
	Successor	Oculis Holding AG (Nasdaq: OCS)
	Industry	finance
	Industry 2	BIOTECH
	Person	Bravo, Eduardo (Life Sciences Partners 202103– Partner + CEO of EBAC before Nordic Nanovector + TiGenix + Cellerix)
	Person 2	Kleijwegt, Martijn (Life Sciences Partners 200612 Managing Partner)

		Address record changed: 2023-03-09

Basic data	Employees	n. a.

		* Document for »About Section«: Life Sciences Partners (LSP). (3/18/21). "Press Release: LSP Announces Closing of Upsized $120 Million Nasdaq IPO of European Biotech Acquisition Corp (EBAC) Targeting European Biotech". Amsterdam.

		Record changed: 2023-08-30

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for Oculis (Group)

[1] Oculis Holding AG. (3/3/23). "Press Release: Oculis Announces US Public Listing on NASDAQ". Lausanne & Zug....
[2] Oculis S.A.. (5/4/21). "Press Release: Oculis Announces an Oversubscribed US$57 million Series C Financing". Lausanne....
[3] Life Sciences Partners (LSP). (3/18/21). "Press Release: LSP Announces Closing of Upsized $120 Million Nasdaq IPO of European Biotech Acquisition Corp (EBAC) Targeting European Biotech". Amsterdam....
[4] Oculis S.A.. (9/1/20). "Press Release: Oculis Establishes Presence in U.S. and Appoints Sylvia Cheung as Chief Financial Officer". Lausanne....
[5] Oculis S.A.. (1/4/19). "Press Release: Oculis Raises CHF15.5 Million in an Extension of Its Series B Financing Round – Total Raised CHF35.5 Million". Lausanne....
[6] Oculis S.A.. (1/4/19). "Press Release: Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF alpha Antibody Fragment". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

» top